Table I.
Pre- and one-year post-HSCT patient characteristics including chronic pain categories by AAPT criteria pre-HSCT (n = 35).
| Acute episodic pain only (n = 16) | Chronic pain without SCD complications (AAPT subtype 1) (n = 4) | Chronic pain with SCD complications (AAPT subtype 2) (n = 9) | Chronic pain with mixed pain phenotype (AAPT subtype 3) (n = 6) | |
|---|---|---|---|---|
| Age at HSCT (years) | 25 (16—41) | 34–5 (23–65) | 36 (22–53) | 34 (19–47) |
| Gender | 6 F + 10 M | 3 F + 1 M | 2 F + 7 M | 3 F + 3 M |
| Hydroxycarbamide pre-HSCT (mg) | 1250 (500–2500) | 2000 (1500–2500) | 1500 (1000–2000) | 1750 (500–2000) |
| Pre-HSCT | Post-HSCT | Pre-HSCT | Post-HSCT | Pre-HSCT | Post-HSCT | Pre-HSCT | Post-HSCT | |
|---|---|---|---|---|---|---|---|---|
| Admissions for pain/year n (range) | 2 (0–24) | 0 (0) | 6 (3–9) | 0–5 (0–2) | 2 (0–10) | 0 (0) | 4–5 (3–15) | 0 (0–3) |
| Short–acting opioids use n (%) | 13/16 (81%) | 0 (0) | 4/4 (100%) | 4/4 (100%) | 9/9 (100%) | 5/9 (56%) | 6/6 (100%) | 5/6 (83%) |
| Long-acting opioids use n (%) | 1/16 (6–25%) | 0 (0) | 4/4 (100%) | 1/4 (25%) | 5/9 (56%) | 1/9 (11%) | 3/6 (50%) | 3/6 (50%) |
| Haemoglobin (g/1) | 92 (72–105) | 135 (102–168) | 90 (74–92) | 106 (72–126) | 83 (67–105) | 142 (99–195) | 88 (77–98) | 119 (105–135) |
| Donor red cell phenotype achieved | N/A | Yes | N/A | Yes | N/A | Yes | N/A | Yes |
AAPT, ACTTION- American Pain Society Pain Taxonomy; HSCT, haematopoietic stem cell transplant; N/A, not applicable; SCD, sickle cell disease. Data displayed as median and range.